Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 2,353 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Positron emission tomography Clear all

Conditions: Traumatic Brain Injury
Interventions: Cognitive/Neuropsychological Testing, Vestibular/Ocular-Motor Testing, Sleep Evaluation, MRI, High-Resolution, Health & Physical Exam, Physical Function, Blood Testing and Biomarker Analysis, Applanation Tonometry, PET brain imaging, [C-11]6-OH-BTA-1, [F-18]AV-1451; Diagnostic Test · Drug
Lead sponsor: David Okonkwo, MD, PhD; Other
Eligibility: 29 Years to 59 Years · Male only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Cancer Diagnosis
Interventions: PSMA PET scan, No PSMA PET, 18F- DCFPyl Injection; Diagnostic Test · Other · Drug
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cancer
Interventions: [18F]fluoro-2-deoxy-D-glucose (FDG); Drug
Lead sponsor: University of Utah; Other
Eligibility: Not listed
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cocaine Dependence
Interventions: Psychiatric and Cognitive Testing, Cocaine Self-adminstration, Positron Emission Tomography, Magnetic Resonance Imaging; Behavioral · Drug · Radiation + 1 more
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cancer
Interventions: WB-DW-MR scan, 18-F-FDG PET scan, Ferumoxytol, 18-F-FDG PET/MR scan; Procedure · Drug
Lead sponsor: Stanford University; Other
Eligibility: 6 Years to 40 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma, Refractory Ovarian Carcinoma
Interventions: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, X-Ray Imaging; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 9
States / cities: Bethesda, Maryland • New York, New York • The Bronx, New York + 3 more

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Fludeoxyglucose F-18, Immunotherapy, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years to 74 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Parkinson Disease
Interventions: [18F]MK-9470; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 18 Years to 90 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cervical Cancer, HEENT Cancer, Renal Cancer, Uterine Cancer, CERVIX UTERI NOS, RECTUM
Interventions: 124I-Iodo-Azomycin Galacto-Pyranoside; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Neurofibromatosis, MPNST
Interventions: MRI, FDG-PET/CT scans, [18F]-FLT-PET/CT scans; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 10 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma, Refractory Neuroblastoma
Interventions: Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Dinutuximab, Echocardiography Test, FDG-Positron Emission Tomography, Iberdomide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nuclear Radiology Imaging Procedure, Sargramostim, Topotecan; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 4
States / cities: Oakland, California • Chicago, Illinois • New York, New York + 1 more

Conditions: Lymphoma
Interventions: Fludeoxyglucose F18, Computed Tomography, Positron emission tomography; Radiation · Procedure
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Systemic Lupus Erythematosus
Interventions: Not listed
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Head and Neck Cancer
Interventions: cetuximab, cisplatin, TdT-mediated dUTP nick end labeling assay, 3'-deoxy-3'-[18F]fluorothymidine, immunohistochemistry staining method, laboratory biomarker analysis, fludeoxyglucose F 18, radiation therapy; Biological · Drug · Genetic + 2 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Metastatic Cancer, Prostate Cancer
Interventions: antiandrogen therapy, docetaxel, C-11 acetate PET scan, F-18 FDG PET scan, Tc-99m bone scan, CT scan of the chest, abdomen and pelvis; Drug · Diagnostic Test
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Painful Joint Prostheses
Interventions: FDG-PET Imaging; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Participants, Idiopathic Pulmonary Fibrosis (IPF)
Interventions: 18F-BMS-986327; Diagnostic Test
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Down Syndrome, Alzheimer's Disease
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 21 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: (Un)predictable and (un)attended stimuli; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years to 35 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Progressive Supranuclear Palsy (PSP), Healthy Participants
Interventions: [18F]ABBV-964i, [18F]ABBV-965i, Lead Candidate; Drug
Lead sponsor: Invicro; Other
Eligibility: 18 Years to 80 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Rituximab, Tafasitamab; Procedure · Biological
Lead sponsor: Timothy Voorhees; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: New Brunswick, New Jersey • Hillsborough, North Carolina • Columbus, Ohio + 1 more

Conditions: Stage I Lung Cancer, Stage I Non-Small Cell Lung Cancer AJCC v7, Stage IA Non-Small Cell Lung Carcinoma AJCC v7, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Lung Cancer, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7
Interventions: Fludeoxyglucose F-18, Positron Emission Tomography (PET), Stereotactic Body Radiation Therapy (SBRT); Drug · Procedure · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Solid Tumor, Adult, Solid Tumor, Metastatic Castration-resistant Prostate Cancer
Interventions: Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, 11C-YJH08, Optional Tumor Biopsy; Procedure · Drug
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction, Recurrent Esophageal Cancer, Squamous Cell Carcinoma of the Esophagus, Stage IV Esophageal Cancer
Interventions: pralatrexate, docetaxel, fludeoxyglucose F 18, positron emission tomography; Drug · Radiation · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

University of Pittsburgh Brain Health Initiative

PSMA PET Scan and mpMRI for Prostate Cancer Detection

FDG-Positron Emission Tomography (PET)/CT In the Evaluation of Persistent Febrile Neutropenia in Cancer Patients

Investigation of Cocaine Addiction Using mGluR5 PET and fMRI

Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects

Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors

Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)

Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus

3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx

Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone

FDG-PET Imaging in Painful Joint Prosthesis

A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327

Amyloid Plaque and Tangle Imaging in Alzheimer's Disease and Down Syndrome

The Brain Metabolism of Unpredictable Signals

First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy

11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression

Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy